Delivering Better Cancer Care to Those in Need

Delivering Better Cancer Care

Removing the barriers to better cancer care is a significant challenge in many countries worldwide. Partnering with different stakeholders across the health eco-system and playing our part to ensure that every patient has the opportunity to achieve optimal care is a responsibility that we at Bayer take seriously.

Learn more about the importance of collaboration in the fight against cancer:

The latest innovations in cancer care are not accessible to all patients for a variety of reasons, such as geography, lack of infrastructure to deliver care, delays in reimbursement for testing and treatment, and lack of awareness. This results in significant disparities in access to quality cancer care. Even within the same country, some patients have access to optimal treatment and care whilst others do not. Lack of access to comprehensive testing and early, optimal treatment can have a significant impact on the outcome of the therapy and thus on the life of the patients and their families.

 

We believe that every patient diagnosed with cancer should be able to access breakthrough innovations and medicines that are appropriate for them as an individual and can bring a meaningful difference to their lives.

Improving Access to Quality Cancer Care in Under-Served Communities

As part of the Oncology Sustainability Initiative at Bayer, we are working across the globe on projects that are primarily focused on improving access to quality cancer care for large, underserved communities in low- and middle-income countries – which experience disparities in access to cancer care.

The Oncology Sustainability blueprint is a key component of Bayer Oncology’s vision to transform the lives of people impacted by cancer through science and innovation. Each project leverages synergies within Bayer by facilitating collaboration among global, regional and local cross-functional teams. The Oncology sustainability projects also involve external collaborations with a diverse set of collaborators, including governments, thought leaders in academia as well as leading cancer centers around the globe to build impactful long-term public-private partnerships. This global collaboration including multiple countries, global health experts and public health agencies is essential for the success of our Bayer Oncology sustainability projects and to improve the quality of cancer care and outcomes in underserved communities.
Chitkala Kalidas PhD
,
Bayer’s Global Head of Oncology Sustainability Initiative and Oncology Regulatory Affairs

India: Improving access to early cancer screening

One landmark Oncology Sustainability project is the partnership between Bayer and the National Cancer Institute of India-All India Institute of Medical Sciences (NCI-AIIMS) located in Jhajjar, Haryana. This collaboration, which was initiated in 2021, brings cancer screening to patients at high risk of cancer in underserved rural communities in India, helping to reduce disparities in access to cancer care.

Bayer India
Colleagues from Bayer in India as well as the Global Research & Development team kick off the oncology sustainability initiative with NCI-AIIMS

Currently, more than 4.5 million people in India suffer from cancer, which is one of the country’s growing non-communicable diseases. It is also the second leading cause of death in India, after cardiovascular disease.

It is the joint goal of Bayer and NCI-India that this effort is not limited to just an initial five-year period. We aim to embed this work in the operating model of NCI-AIIMS which specializes in providing preventive, curative and palliative care to patients who live in remote villages and do not have easy access to cancer care in metropolitan cities.
Chitkala Kalidas PhD
,
Bayer’s Global Head of Oncology Sustainability Initiative and Oncology Regulatory Affairs

Bayer continues to support this landmark project which is focused on targeted screening in high-risk individuals in order to detect cancer in its early stages and help ensure that patients receive timely treatment and care. Mobile technology is used so that screening, a starting point in quality cancer care, can be delivered to those patients living in remote, rural locations.

 

The five-year initiative includes plans to launch screening programs for prostate, head and neck/oral cancer. It will enable screening of approximately 12,000 patients in the geographical vicinity of NCI, thereby enhancing cancer surveillance and benefitting individuals who may otherwise never be able to find quality cancer care.

The proposed AIIMS-Bayer India joint research initiative is aligned with our institutional objective to develop and establish evidence-based mandates for cancer prevention and control in India. Through this sustainability-initiative, we plan to forge collaborations with local communities, their representatives and with the existing public health system (urban and rural health centers). The implementation and outcomes of the proposed program will be instrumental in developing effective strategies for cancer screening and early diagnosis. With further capacity building and improved referral networking between local health system and NCI-AIIMS through this initiative, we plan to continue and expand the coverage and scope of these screening activities with provision of high-quality cancer treatment and care for cancer suspects.
Dr Hari Sagiraju
,
(Assistant Professor- Preventive Oncology, NCI-AIIMS) Project PI

Egypt: Working with the Egyptian Ministry of Health and Population

In Egypt, liver cancer or hepato-cellular carcinoma (HCC) is the second most common cancer in men, and the sixth most common in women.1 The HCC prevalence rate in the country is above the global average, yet patient outcomes remain below international standards.

 

Bayer has initiated a collaboration with the Egyptian Ministry of Health and Population (MHOP) to support access to HCC screening, diagnosis and treatment in the country. This partnership will work in three ways to improve patient outcomes.

 

The first will be to strengthen the healthcare system to ensure consistent quality of care, and better use of data for decision-making in treatment and care. The second will be to support development of healthcare service capacities through medical education and training programs, and the third to raise patient awareness through education in order to develop knowledge of cancer management and create demand for quality treatment and care. The partners have set themselves ambitious goals, and first results of this program are expected to be seen from as early as 2022.

Members of the Egyptian MOHP and Bayer in Egypt collaboration team
Members of the Egyptian MOHP and Bayer in Egypt collaboration team

Looking towards the future

Whether it is through educational campaigns, projects that make cancer screening and diagnosis more accessible, or by enabling health services to increase their capacity to provide better care, this initiative provides the opportunity to reach over 300 million patients worldwide. It works towards our collective goals as a cancer network to save as many lives as possible from cancer and to make a positive difference to the lives of all those affected by it.

 

Bayer is committed to continuing to drive forward innovative and impactful, new initiatives focused on underserved communities in partnership with leading organizations in order to help address inequities in cancer care across the world. Together we can make ‘Health for All’ a reality for people with cancer around the globe and ensure that no-one is left behind.

 

Learn more about the importance of collaboration in the fight against cancer.


1 Rashed, W.M., Mohamed Kandeil, M.A., Mahmoud, M.O. et al. Hepatocellular Carcinoma (HCC) in Egypt: A comprehensive overview. Journal of the Egyptian National Cancer Institute. 32; 5 2020